CVS Stock Falls After Karen Lynch Ouster: What to Know
CVS stock is lower Friday after the embattled healthcare company said Karen Lynch is out as CEO, effective immediately.


CVS Health (CVS) stock is spiraling Friday after the pharmacy chain and health benefits provider announced the appointment of a new CEO.
Effective October 17, David Joyner took over as president and CEO of CVS Health, replacing Karen Lynch, who had been in the position since February 2021. Joyner has 37 years of experience in the healthcare and pharmacy benefit management industries, most recently serving as executive vice president of CVS Health and president of CVS Caremark.
"There is no greater honor than to lead a company whose mission and purpose are completely focused on improving health," Joyner said in a statement. "I came back to CVS Health in 2023 because I believed I could give more to the company, and I take this opportunity today for the same reason. I am proud to continue working side by side with our 300,000 colleagues who are building a world of health around every consumer."

Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The news comes less than three weeks after reports surfaced that CVS was conducting a strategic review of its business and had hired bankers to assist in exploring options, including a possible breakup of its retail and insurance units.
CVS Health's preliminary Q3 results fall short
In the press release, CVS also provided preliminary guidance for its third quarter, calling for earnings per share in the range of $1.05 to $1.10.
The forecast falls well below analysts' expectations for third-quarter earnings of $1.70 per share, according to Yahoo Finance.
"In light of continued elevated medical cost pressures in the Health Care Benefits segment, investors should no longer rely on the Company's previous guidance provided on its second-quarter 2024 earnings call on August 7, 2024," CVS added.
Is CVS stock a buy, sell or hold?
CVS Health has had a rough year on the price charts, as well. Shares have fallen more than 26% since the start of 2024, but Wall Street remains bullish on the healthcare stock.
According to S&P Global Market Intelligence, the average analyst target price for CVS is $70.10, representing implied upside of 20% to current levels. Additionally, the consensus recommendation is Buy.
Financial services firm Argus Research is one of those with a Buy rating the large-cap stock and a $75 price target.
The shares trade at an attractive valuation and CVS boasts a healthy 4.2% dividend yield which seems sustainable, wrote Argus Research analyst Christopher Graja in an October 2 note. However, the analyst admitted that he's "disappointed with the recent performance of the Health Care Benefits business" and is "not sure that our Buy recommendation can withstand another guidance cut or a deterioration in credit-quality metrics."
Related content
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Joey Solitro is a freelance financial journalist at Kiplinger with more than a decade of experience. A longtime equity analyst, Joey has covered a range of industries for media outlets including The Motley Fool, Seeking Alpha, Market Realist, and TipRanks. Joey holds a bachelor's degree in business administration.
-
Stock Market Today: Trump Retreats, Markets Rejoice
Stocks rally, yields soften, the dollar rises, and even beaten-down names enjoy the wages of potential trade peace.
By David Dittman
-
In Trump’s Economy Should 401(k) Savers 'Set It and Forget It?'
It’s hard to bury your head in the sand when the markets are volatile. Here’s when it makes sense and when it doesn’t.
By Donna Fuscaldo
-
Stock Market Today: Trump Retreats, Markets Rejoice
Stocks rally, yields soften, the dollar rises, and even beaten-down names enjoy the wages of potential trade peace.
By David Dittman
-
Tesla Stock Pops as Elon Musk Promises DOGE Draw Back
Tesla reported a sharp drop in first-quarter earnings and sales, as the EV maker suffered a backlash to its CEO's political ambitions.
By Karee Venema
-
Bouncing Back: New Tunes for Millennials Trying to Make It
Adele's mournful melodies kick off this generation's financial playlist, but with the right plan, Millennials can finish strong.
By Alvina Lo
-
Early-Stage Startup Deals: How Do Convertible Notes Work?
Some angel investors support early startups by providing a loan in exchange for a convertible note, which includes annual interest and a maturity date.
By Murat Abdrakhmanov
-
Stock Market Today: Stocks Soar on China Trade Talk Hopes
Treasury Secretary Bessent said current U.S.-China trade relations are unsustainable and signaled hopes for negotiations.
By Karee Venema
-
How Can Investors Profit From AI's Energy Use?
Global energy demand is expected to grow by leaps and bounds over the next several years as AI usage accelerates. Here's how to get a piece of the pie.
By Jacob Schroeder
-
Can Trump Fire Powell? A Supreme Court Case Could Decide
Presidential posts threaten to overwhelm decades of precedent and tradition, whatever the nine justices decide.
By David Dittman
-
What Are AI Agents and What Can They Do for You?
AI agents promise to be the next big thing in artificial intelligence, but what exactly do they do?
By Tom Taulli